[Efficacy and safety of medicinal cannabis: results of the CaPRis study].
Wirksamkeit und Sicherheit von Cannabisarzneimitteln: Ergebnisse der CaPRis-Studie.
CBD
Cannabis medicine
Health problems
Medicinal cannabis
Mental disorders
THC
Journal
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
ISSN: 1437-1588
Titre abrégé: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Pays: Germany
ID NLM: 101181368
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
pubmed:
20
6
2019
medline:
19
9
2019
entrez:
20
6
2019
Statut:
ppublish
Résumé
In the 1990s, the endocannabinoid system was discovered as part of the human physiology. Since then, the effects of cannabis as a medicine have been researched more systematically. To summarize the scientific knowledge, the German Federal Ministry of Health commissioned an expertise.The project "Cannabis: Potential and Risks: a Scientific Analysis" (CaPRis), which started in 2016, aimed at analyzing the potential of medicinal cannabis and the risks of recreational cannabis use. A search of systematic reviews (SRs) and randomized-controlled trials (RCTs) were conducted in five international databases (publication date: 2006-2017). For the medical use of cannabis 16 SRs (of 186 RCTs) were included from a global search and nine further RCTs were comprised from a de novo search. All studies were methodologically assessed.Evidence for the efficacy of cannabis medicine (given as an adjunct to other medication) was found in patients with chronic pain and spasticity due to multiple sclerosis. Benefits were also found for appetite stimulation, improvement of nausea, and weight gain in patients with cancer, HIV/AIDS or in palliative care. Effects were often small. For other physical or mental disorders, only few or no controlled human studies are available. Adverse effects of cannabis medicine are often reported; severe adverse effects were mentioned in single cases only.To provide reliable treatment recommendations for clinicians and patients, more large-sized RCTs with follow-up assessments, consistent outcome measures, and active comparisons are needed.
Identifiants
pubmed: 31214723
doi: 10.1007/s00103-019-02965-3
pii: 10.1007/s00103-019-02965-3
doi:
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM